SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
EPS Over TimeExpanding
Percentile Rank83
5Y CAGR-45.6%
Studio
Year-over-Year Change

Earnings per share

5Y CAGR
-45.6%/yr
Long-term compound
Percentile
P83
Within normal range
vs 5Y Ago
0x
Contraction
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM0.22+106.0%
2024-3.68+51.8%
2023-7.64-77.3%
2022-4.31-9.4%
2021-3.94-185.1%
20204.63+2204.5%
2019-0.22-